Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E-ZO-FAST: Zoledronic Acid for Bone Loss in Breast Cancer
NCT00171314Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2004
- Primary completion
- Nov 2010
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, open-label trial of zoledronic acid in osteoporosis (2 arms), sponsored by Novartis. Primary endpoint: Percent Change in Lumbar Spine (L2-L4) BMD at 12 months. Started Mar 2004; status: completed.
02
Drugs
zoledronic acid
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT00171314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00171314.